Researching peptidomimetics to improve RMS treatment
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma that occurs in children. The survival rate is between 30% and 65%. Given these figures, more specific and effective therapies are needed to tackle this condition. A novel signalling pathway involved in a wide variety of cancer types, including RMS, has been discovered by Dr. Josep Roma, at Vall d'Hebron Research Institute (VHIR) in Barcelona). In this pathway, a PPI triggers the event cascade that culminates in mitosis and/or carcinogenesis.
Iproteos has designed a family of peptidomimetics that modulate the initial PPI. The molecules are currently being evaluated in vitro. Preliminary results reveal that they are potent in several cancer cell lines.